AB
CRNX icon

Amalgamated Bank’s Crinetics Pharmaceuticals CRNX Stock Holding History

Amalgamated Bank’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,841
Closed -$132K – 1906
2025
Q4 		$132K Sell
2,841
-89
-3% -$3.96K ﹤0.01% 1661
2025
Q3 		$122K Sell
2,930
-229
-7% -$7.32K ﹤0.01% 1665
2025
Q2 		$91K Hold
3,159
– – ﹤0.01% 1713
2025
Q1 		$106K Buy
3,159
+467
+17% +$17.4K ﹤0.01% 1668
2024
Q4 		$138K Hold
2,692
– – ﹤0.01% 1651
2024
Q3 		$138K Hold
2,692
– – ﹤0.01% 1648
2024
Q2 		$121K Buy
2,692
+464
+21% +$21.4K ﹤0.01% 1679
2024
Q1 		$104K Sell
2,228
-4,271
-66% -$167K ﹤0.01% 1713
2023
Q4 		$231K Buy
6,499
+201
+3% +$6.16K ﹤0.01% 1751
2023
Q3 		$187K Buy
6,298
+592
+10% +$12.2K ﹤0.01% 1807
2023
Q2 		$103K Sell
5,706
-3
-0.1% -$60 ﹤0.01% 2051
2023
Q1 		$92K Sell
5,709
-1,259
-18% -$23.3K ﹤0.01% 2086
2022
Q4 		$128K Hold
6,968
– – ﹤0.01% 2034
2022
Q3 		$137K Buy
6,968
+74
+1% +$1.51K ﹤0.01% 1999
2022
Q2 		$129K Sell
6,894
-334
-5% -$6.67K ﹤0.01% 2067
2022
Q1 		$159K Sell
7,228
-558
-7% -$11.3K ﹤0.01% 2027
2021
Q4 		$221K Buy
+7,786
New +$192K ﹤0.01% 1941

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Amalgamated Bank's CRNX Position: Q1 2026 in Review

Amalgamated Bank sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 2,841 shares — an estimated $132K sold.

Amalgamated Bank first reported a position in CRNX in Q4 2021 and held it in 17 quarters. The position peaked at $231K in Q4 2023. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Amalgamated Bank reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 2,841 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $132K.
  • Amalgamated Bank first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 17 quarters.
  • Amalgamated Bank's Crinetics Pharmaceuticals position peaked at $231K in Q4 2023.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.